Abstract
Imatinib mesylate is used with increasing frequency and duration for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), and other neoplastic conditions. Although muscular complaints are common, elevations of creatine kinase (CK) are listed as <1% in the product label. We describe here a case of rhabdomyolysis likely related to imatinib as well as the results of a prospective evaluation of CK levels in a cohort of patients on imatinib for CML or GIST. We found a high prevalence of CK abnormalities in this group and believe that CKs should be monitored during therapy with imatinib.
Copyright 2009 Elsevier Ltd. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Case-Control Studies
-
Cohort Studies
-
Creatine Kinase / blood*
-
Edema / blood
-
Edema / chemically induced
-
Female
-
Gastrointestinal Stromal Tumors / blood
-
Gastrointestinal Stromal Tumors / drug therapy
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Middle Aged
-
Muscular Diseases / blood
-
Muscular Diseases / chemically induced
-
Piperazines / adverse effects
-
Piperazines / therapeutic use*
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Up-Regulation / drug effects
-
Young Adult
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Creatine Kinase